Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000033305 | SCV000057210 | pathogenic | not provided | 2022-06-02 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; Missense variants in this gene are often considered pathogenic (HGMD); This variant is associated with the following publications: (PMID: 26150740, 23093928, 17551924, 24803665, 31263281, 16439621, 18042262, 24957944, 15488754, 15520807, 17603483) |
Laboratory for Molecular Medicine, |
RCV000037917 | SCV000061579 | pathogenic | Cardio-facio-cutaneous syndrome | 2009-06-02 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000797502 | SCV000937062 | pathogenic | RASopathy | 2021-12-01 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BRAF protein function. ClinVar contains an entry for this variant (Variation ID: 40366). This missense change has been observed in individual(s) with cardio-facio-cutaneous syndrome or other RASopathy disorders (PMID: 16439621, 17551924, 18042262, 29084544). In at least one individual the variant was observed to be de novo. This variant is present in population databases (rs397507473, gnomAD 0.0009%). This sequence change replaces phenylalanine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 468 of the BRAF protein (p.Phe468Ser). |
Hudson |
RCV001293860 | SCV001482525 | pathogenic | Cardiofaciocutaneous syndrome 1 | 2021-02-19 | criteria provided, single submitter | research | ACMG codes:PS2, PS4M, PM1, PM2, PP2, PP3, PP5 |
Genome Diagnostics Laboratory, |
RCV001813222 | SCV002060517 | pathogenic | Noonan syndrome and Noonan-related syndrome | 2019-04-01 | criteria provided, single submitter | clinical testing | |
Ai |
RCV000033305 | SCV002502773 | likely pathogenic | not provided | 2021-10-20 | criteria provided, single submitter | clinical testing | |
Laboratorio de Genetica e Diagnostico Molecular, |
RCV002251944 | SCV002523369 | pathogenic | See cases | 2019-11-29 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PS4, PM1, PM6, PP2, PP3 |
Prevention |
RCV003407389 | SCV004110177 | pathogenic | BRAF-related condition | 2023-02-24 | criteria provided, single submitter | clinical testing | The BRAF c.1403T>C variant is predicted to result in the amino acid substitution p.Phe468Ser. This variant has been reported in at least six individuals with cardio-facio-cutaneous syndrome (Rodriguez-Viciana et al. 2006. PubMed ID: 16439621; Gripp et al. 2007. PubMed ID: 17551924; Nava et al. 2007. PubMed ID: 17704260; Schulz et al. 2007. PubMed ID: 18042262) and one individual with Noonan syndrome (Xu et al. 2017. PubMed ID: 29084544). In at least three individuals this variant occurred de novo (Gripp et al. 2007. PubMed ID: 17551924; Schulz et al. 2007. PubMed ID: 18042262). Additionally, different amino acid substitutions affecting the same (p.Phe468Cys) and adjacent (p.Ser467Ala, p.Gly469Arg, p.Gly469Glu) amino acids have been reported as pathogenic (Human Gene Mutation Database). This variant is reported in 0.00088% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/7-140481405-A-G). This variant is interpreted as pathogenic. |